Praxis Precision Medicines, Inc. announced on December 4, 2025, the successful completion of its pre-New Drug Application meeting with the FDA for ulixacaltamide and reported positive results from the EMBOLD study for relutrigine, showing a 53% reduction in seizures over 16 weeks. Patients achieved a 66% increase in motor seizure-free days, with no serious drug-related adverse events.